FUNDAMENTALS · Fundamentals · TW Consumer Cyclical

Kwong Lung Enterprise (8916) Fundamentals 2026 — P/E 18.0x, Revenue Analysis | SniperIQ

Kwong Lung Enterprise (8916) is a TW-listed Consumer Cyclical company in Apparel - Manufacturers with a market capitalization of NT$6.2B, trading at NT$42.05 on the TWO. This SniperIQ fundamentals page covers Kwong Lung Enterprise's valuation (P/E 18.0x, P/B 1.3x), profitability (net margin 4.2%), revenue (NT$8.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$6.2B
P/E (TTM)18.0x
Net Margin4.2%
Revenue (FY25)NT$8.5B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Kwong Lung Enterprise's market cap?

Kwong Lung Enterprise (8916) has a market capitalization of approximately NT$6.2B, trading at NT$42.05 on the TWO. Market cap moves with the live share price.

What is Kwong Lung Enterprise's P/E ratio?

Kwong Lung Enterprise's trailing twelve-month P/E ratio is 18.0x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.

How profitable is Kwong Lung Enterprise?

Kwong Lung Enterprise runs a net profit margin of 4.2%, a gross margin of 15.0%, and an operating margin of 5.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Kwong Lung Enterprise generate?

Kwong Lung Enterprise reported revenue of NT$8.5B for fiscal year 2025, with net income of NT

77M and earnings per share (EPS) of 2.5. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Kwong Lung Enterprise pay a dividend?

Kwong Lung Enterprise offers a trailing dividend yield of about 8.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Kwong Lung Enterprise financially healthy?

Kwong Lung Enterprise carries a debt-to-equity ratio of 0.61x and a current ratio of 1.06x, with a market beta of -0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Kwong Lung Enterprise a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kwong Lung Enterprise (8916) the key facts are: market cap NT$6.2B, P/E 18.0x, revenue NT$8.5B, 52-week range 41.95-51.9. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.

Track Kwong Lung Enterprise's full fundamentals live

Get Kwong Lung Enterprise's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.